$68.77
2.28% today
Nasdaq, Jun 06, 10:00 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$68.77
+9.16 15.37% 1M
-7.15 9.42% 6M
-0.30 0.43% YTD
+10.36 17.74% 1Y
-25.81 27.29% 5Y
-38.23 35.73% 10Y
+61.67 868.59% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+1.53 2.28%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Market capitalization $13.02b
Enterprise Value $10.64b
P/E (TTM) P/E ratio 672.40
EV/FCF (TTM) EV/FCF 35.16
EV/Sales (TTM) EV/Sales 2.41
P/S ratio (TTM) P/S ratio 2.95
P/B ratio (TTM) P/B ratio 3.55
Revenue growth (TTM) Revenue growth 17.13%
Revenue (TTM) Revenue $4.41b
EBIT (operating result TTM) EBIT $237.97m
Free Cash Flow (TTM) Free Cash Flow $302.71m
Cash position $2.41b
EPS (TTM) EPS $0.10
P/E forward 15.56
P/S forward 2.76
EV/Sales forward 2.26
Short interest 6.93%
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Incyte forecast:

13x Buy
45%
15x Hold
52%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Incyte forecast:

Buy
45%
Hold
52%
Sell
3%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4,413 4,413
17% 17%
100%
- Direct Costs 300 300
27% 27%
7%
4,113 4,113
16% 16%
93%
- Selling and Administrative Expenses 1,247 1,247
9% 9%
28%
- Research and Development Expense 2,604 2,604
58% 58%
59%
262 262
64% 64%
6%
- Depreciation and Amortization 24 24
5% 5%
1%
EBIT (Operating Income) EBIT 238 238
67% 67%
5%
Net Profit 21 21
97% 97%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
Business Wire
about one hour ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Neutral
Business Wire
3 days ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025.
Positive
Market Watch
4 days ago
When selecting investments, it is easy to get hung up on a particular metric, such as a dividend yield or a price ratio, but investors need to look deeper or they might miss opportunities.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,617
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today